Blue­bird joins the lay­off flock to re­al­i­ty as gene ther­a­py biotech sheds staff to save it­self

Blue­bird bio is lay­ing off about 30% of its work­force to save it­self be­fore the FDA de­cides the fate of two of its gene ther­a­pies in Au­gust and Sep­tem­ber and plans to file for a third ap­proval in the first quar­ter of next year.

The dire sit­u­a­tion came in­to clear view ear­li­er this year when blue­bird said in a quar­ter­ly fil­ing its cash prob­lems “raise sub­stan­tial doubt re­gard­ing its abil­i­ty to con­tin­ue as a go­ing con­cern” in the com­ing year. The CFO re­signed the same day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER